Fred Hutchinson Cancer Research Center
Mustang Bio Reports Positive Phase I/II Data for CD20-Targeted CAR T-Cell Therapy
Patients with Waldenstrom macroglobulinemia had favorable responses to a CD20-directed CAR T-cell therapy in a Phase I/II trial.
Mustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseases
The firm has not disclosed which autoimmune indications it is considering as part of a potential trial led by Fred Hutchinson Cancer Center researchers.
Exome sequencing of more than 17,000 men with prostate cancer identified known and novel gene variants linked to risk of aggressive disease.
Proteomic Signature Shows Promise in Identifying Ovarian Cancer Patients Who Won't Respond to Chemo
Premium
Where single biomarkers have failed to identify refractory ovarian cancers before treatment, a 64-protein signature could with 98 percent specificity.
Fred Hutch Cancer Center's MET-X Program Wants to Study Metastasis, Stop Tumor Cells Spreading
Premium
The program will foster and fund innovative, high-risk research with the goal of elucidating the biological underpinnings of metastasis in all types of cancer.
Jul 7, 2021